Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Sarcoma

 

Trabectedin or Dacarbazine Advanced L-Sarcoma (20110545)
A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated With an Anthracycline and Ifosfamide

Investigator: Robin L. Jones, MD;   Conditions: Liposarcoma, Leiomyosarcoma;    Status: Recruiting;   Study ID: NCT01343277

Trabectedin for Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma (20051530)
A Multicenter, Open-label Single-arm Study of YONDELIS® (trabectedin) for Subjects with Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment

Investigator: Robin L. Jones, MD;   Conditions: Sarcoma;    Status: Recruiting;   Study ID: NCT00210665

Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma (COG ARST0332)
Risk-Based Treatment for Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS)

Investigator: Doug Hawkins, MD;   Conditions: Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma;    Status: Recruiting;   Study ID: NCT00346164

Eribulin or Dacarbazine for Leiomyosarcoma and Liposarcoma (UW11016)
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

Investigator: Robin L. Jones, MD;   Conditions: Soft Tissue Sarcoma;    Status: Closed;   Study ID: NCT01327885

Pazopanib Hydrochloride Followed By Chemotherapy and Surgery for Soft Tissue Sarcoma
The Effect of Antiangiogenic Therapy With Pazopanib Prior to Preoperative Chemotherapy for Subjects With Extremity Soft Tissue Sarcomas: A Randomized Study to Evaluate Response by Imaging

Investigator: Robin L. Jones, MD;   Conditions: Soft tissue sarcoma;    Status: Recruiting;   Study ID: NCT01446809

Ramucirumab + Docetaxel for Malignant Solid Tumors
A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Docetaxel in Patients With Advanced Malignant Solid Tumors

Investigator: Laura Q.M. Chow, MD;   Conditions: Malignant Solid Tumor;    Status: Closed;   Study ID: NCT01567163

Ramucirumab + Paclitaxel for Malignant Solid Tumors
A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Paclitaxel in Patients With Advanced Malignant Solid Tumors

Investigator: Laura Q.M. Chow, MD;   Conditions: Malignant Solid Tumor;    Status: Closed;   Study ID: NCT01515306

ID-LV305 for Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1
A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1

Investigator: Seth M. Pollack, MD;   Conditions: Breast Cancer, Melanoma, Non-small Cell Lung Cancer, Ovarian Cancer, Sarcoma;    Status: Recruiting;   Study ID: NCT02122861

MPDL3280A + Cobimetinib for Locally Advanced or Metastatic Cancer
A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

Investigator: Laura Chow, MD;   Conditions: Neoplasms;    Status: Closed;   Study ID: NCT01988896

NY-ESO-1 Specific T Cells After Cyclophosphamide for Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (2720)
A Study To Determine the Feasibility of Treating Synovial Sarcoma and Myxoid/ Round Cell Liposarcoma using Autologous NY-ESO-1 Specific CD8+ T Cells with Cyclophosphamide Pre-Conditioning but Without the Use of IL-2

Investigator: Seth Pollack;   Conditions: Sarcoma;    Status: Recruiting;   Study ID: NCT02059850